The primary purpose of this study is to evaluate the feasibility and estimate the efficacy of psilocybin-facilitated treatment for cocaine use. We also will monitor the impact of psilocybin-facilitated treatment on the use of other drugs and outcomes relevant to cocaine involvement. MRI assessment is a unique aspect of this study. As a potential biological mechanism of psilocybin's effect includes changes in default mode network functional connectivity (Carhart-Harris et al., 2012), we will determine if psilocybin's therapeutic effects are mediated by such changes. Moreover, as Glx (a brain metabolite that reflects glutamate) abnormalities have been shown to play a role in cocaine addiction, we will determine if psilocybin impacts Glx in the anterior cingulate cortex and hippocampus.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The difference between the psilocybin and placebo groups in the percentage of days abstinent from cocaine, verified by urine drug screen.
Timeframe: From the psilocybin or placebo administration session to end-of-treatment (approximately 4 weeks in most participants), from end-of-treatment to 12 weeks after end-of-treatment, and from 12 weeks after end-of-treatment to 24 weeks after end-of-treatment.
The difference between the psilocybin and placebo groups in sustained/complete abstinence from cocaine, verified by urine drug screen.
Timeframe: From the psilocybin or placebo administration session to 24 weeks after end-of-treatment.
The difference between the psilocybin and placebo groups in time to cocaine lapse.
Timeframe: From the psilocybin or placebo administration session to 24 weeks after end-of-treatment.